Table 1.
Patient characteristics according to tumor sidedness (N=135)
| Left sided CRC, N (%) |
Right sided CRC, N (%) |
p-value† |
|
|---|---|---|---|
| Patient Number | 100 (100.0%) | 35 (100.0%) | |
| Age | 1.000 | ||
| <65 | 83 (83.0%) | 29 (82.9%) | |
| ≥65 | 17 (17.0%) | 6 (17.1%) | |
| Sex | 0.558 | ||
| Men | 55 (55.0%) | 17 (48.6%) | |
| Women | 45 (45.0%) | 18 (51.4%) | |
| ECOG | 0.335 | ||
| 0 | 6 (6.0%) | 4 (11.4%) | |
| 1-2 | 94 (94.0%) | 31 (88.6%) | |
| Disease status | 1.000 | ||
| Metastatic | 67 (67.0%) | 24 (68.6%) | |
| Recurrent | 33 (33.0%) | 11 (31.4%) | |
| KRAS mutation | 0.146 | ||
| Wild | 53 (53.0%) | 14 (40.0%) | |
| Mutant | 35 (35.0%) | 18 (51.4%) | |
| Unknown | 12 (12.0%) | 3 (8.6%) | |
| Number of previous systemic anticancer therapies for metastatic disease | 0.326 | ||
| ≤3 | 46 (46.0%) | 20 (57.2%) | |
| >3 | 54 (54.0%) | 15 (42.9%) | |
| Metastatic site | 0.828 | ||
| 1-2 | 71 (71.0%) | 26 (74.3%) | |
| ≥3 | 29 (29.0%) | 9 (25.7%) | |
* CRC; colorectal cancer. Left side colon cancer: splenic flexure to proximal third of the transverse colon. Right side colon cancer: cecum to distal two-thirds of the transverse colon. † p value is calculated by chi-square test.